Ann: Trading Halt, page-254

Gee i missed all the fun. up, down, sideways.
You couldn't say that the commentaries were
PARsimonious,

My thinking is like Schultz. I don't know, but i will by tomorrow, know something.
One thing i do know i want is for PR to step down from one of his roles.

My guess is that PAR's submission had loose ends, and the FDA would like a singularly clear submission.
So should we.
PAR needing to have regulatory consultants review indicates another month or 2 to me,
OR
PAR now have the go ahead with stipulations, and there's money involved (We know or should know that there isn't enough to complete the whole Phase III without a CR (at $10m a quarter) )
Very happy to be wrong.

The second thing i want is for an EU submission, after 002, with truncated, narrowed other trial readouts. THat would require board that is able to think outside the box labelled FDA.

It's our company so we should press for what we want. No more back and forth.

IMO. GLTAH. DYOR.